{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:31:50Z","timestamp":1788517910545,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010018","name":"Doctoral Start-up Foundation of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971209"],"award-info":[{"award-number":["31971209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.1038\/s41416-025-03253-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:27:40Z","timestamp":1762190860000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation"],"prefix":"10.1038","volume":"134","author":[{"given":"Jingyuan","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-247X","authenticated-orcid":false,"given":"Ying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-5110","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"3253_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3253_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","volume":"161","author":"B Gu","year":"2021","unstructured":"Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021;161:573\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.036.","journal-title":"Gynecol Oncol"},{"key":"3253_CR3","doi-asserted-by":"publisher","unstructured":"Szab\u00f3 R, R\u00e1cz CP, Dulf FV. Bioavailability improvement strategies for icariin and its derivates: a review. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23147519.","DOI":"10.3390\/ijms23147519"},{"key":"3253_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.663776","volume":"12","author":"F Xu","year":"2021","unstructured":"Xu F, Wu Q, Li L, Gong J, Huo R, Cui W. Icariside II: anticancer potential and molecular targets in solid cancers. Front Pharm. 2021;12:663776. https:\/\/doi.org\/10.3389\/fphar.2021.663776.","journal-title":"Front Pharm"},{"key":"3253_CR5","doi-asserted-by":"publisher","unstructured":"Chen M, Wu J, Luo Q, Mo S, Lyu Y, Wei Y, et al. The anticancer properties of Herba epimedii and its main bioactive components icariin and icariside II. Nutrients. 2016;8. https:\/\/doi.org\/10.3390\/nu8090563.","DOI":"10.3390\/nu8090563"},{"key":"3253_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.7150\/ijbs.11595","volume":"11","author":"M Khan","year":"2015","unstructured":"Khan M, Maryam A, Qazi JI, Ma T. Targeting apoptosis and multiple signaling pathways with icariside ii in cancer cells. Int J Biol Sci. 2015;11:1100\u201312. https:\/\/doi.org\/10.7150\/ijbs.11595.","journal-title":"Int J Biol Sci"},{"key":"3253_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00309-y","volume":"10","author":"Y Cicir\u00f2","year":"2021","unstructured":"Cicir\u00f2 Y, Sala A. Myb oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis. 2021;10:19. https:\/\/doi.org\/10.1038\/s41389-021-00309-y.","journal-title":"Oncogenesis"},{"key":"3253_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.244","volume":"8","author":"J Musa","year":"2017","unstructured":"Musa J, Aynaud M-M, Mirabeau O, Delattre O, Gr\u00fcnewald TG. Mybl2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8:e2895. https:\/\/doi.org\/10.1038\/cddis.2017.244.","journal-title":"Cell Death Dis"},{"key":"3253_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3892\/ol.2021.12427","volume":"21","author":"Y Jin","year":"2021","unstructured":"Jin Y, Qi G, Chen G, Wang C, Fan X. Association between B-Myb proto-oncogene and the development of malignant tumors. Oncol Lett. 2021;21:166. https:\/\/doi.org\/10.3892\/ol.2021.12427.","journal-title":"Oncol Lett"},{"key":"3253_CR10","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1038\/s41388-022-02456-x","volume":"41","author":"W Liu","year":"2022","unstructured":"Liu W, Shen D, Ju L, Zhang R, Du W, Jin W, et al. Mybl2 promotes proliferation and metastasis of bladder cancer through transactivation of Cdca3. Oncogene. 2022;41:4606\u201317. https:\/\/doi.org\/10.1038\/s41388-022-02456-x.","journal-title":"Oncogene"},{"key":"3253_CR11","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.7150\/thno.56604","volume":"11","author":"Q Li","year":"2021","unstructured":"Li Q, Wang M, Hu Y, Zhao E, Li J, Ren L, et al. Mybl2 disrupts the Hippo-Yap pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics. 2021;11:5794\u2013812. https:\/\/doi.org\/10.7150\/thno.56604.","journal-title":"Theranostics"},{"key":"3253_CR12","first-page":"389","volume":"11","author":"G Qi","year":"2021","unstructured":"Qi G, Zhang C, Ma H, Li Y, Peng J, Chen J, et al. Cdca8, targeted by Mybl2, promotes malignant progression and olaparib insensitivity in ovarian cancer. Am J Cancer Res. 2021;11:389\u2013415.","journal-title":"Am J Cancer Res"},{"key":"3253_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.919624","volume":"10","author":"G Wang","year":"2022","unstructured":"Wang G, Yan F, Wang Y, Liu Y, Cui J, Yu Z, et al. Visual sensing of \u03b2-glucosidase from intestinal fungus in the generation of cytotoxic icarisid II. Front Chem. 2022;10:919624. https:\/\/doi.org\/10.3389\/fchem.2022.919624.","journal-title":"Front Chem"},{"key":"3253_CR14","first-page":"587","volume":"79","author":"R Canzoneri","year":"2019","unstructured":"Canzoneri R, Lacunza E, Abba MC. Genomics and bioinformatics as pillars of precision medicine in oncology. Medicina. 2019;79:587\u201392.","journal-title":"Medicina"},{"key":"3253_CR15","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/bib\/bbx170","volume":"20","author":"RK Azad","year":"2019","unstructured":"Azad RK, Shulaev V. Metabolomics technology and bioinformatics for precision medicine. Brief Bioinform. 2019;20:1957\u201371. https:\/\/doi.org\/10.1093\/bib\/bbx170.","journal-title":"Brief Bioinform"},{"key":"3253_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"3253_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5582\/bst.2021.01318","volume":"15","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qiu H, Li C, Cai P, Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021;15:283\u201398. https:\/\/doi.org\/10.5582\/bst.2021.01318.","journal-title":"Biosci Trends"},{"key":"3253_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112542","volume":"146","author":"W Xu","year":"2022","unstructured":"Xu W, Li B, Xu M, Yang T, Hao X. Traditional Chinese medicine for precancerous lesions of gastric cancer: a review. Biomed Pharmacother. 2022;146:112542. https:\/\/doi.org\/10.1016\/j.biopha.2021.112542.","journal-title":"Biomed Pharmacother"},{"key":"3253_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u201316. https:\/\/doi.org\/10.1038\/s41573-020-00114-z.","journal-title":"Nat Rev Drug Discov"},{"key":"3253_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113384","volume":"153","author":"A Esmeeta","year":"2022","unstructured":"Esmeeta A, Adhikary S, Dharshnaa V, Swarnamughi P, Ummul Maqsummiya Z, Banerjee A, et al. Plant-derived bioactive compounds in colon cancer treatment: an updated review. Biomed Pharmacother. 2022;153:113384. https:\/\/doi.org\/10.1016\/j.biopha.2022.113384.","journal-title":"Biomed Pharmacother"},{"key":"3253_CR21","doi-asserted-by":"publisher","unstructured":"Maiuolo J, Gliozzi M, Carresi C, Musolino V, Oppedisano F, Scarano F, et al. Nutraceuticals and cancer: potential for natural polyphenols. Nutrients 2021;13. https:\/\/doi.org\/10.3390\/nu13113834.","DOI":"10.3390\/nu13113834"},{"key":"3253_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110734","volume":"131","author":"S Wang","year":"2020","unstructured":"Wang S, Zhang S, Wang S, Gao P, Dai L. A comprehensive review on Pueraria: insights on its chemistry and medicinal value. Biomed Pharmacother. 2020;131:110734. https:\/\/doi.org\/10.1016\/j.biopha.2020.110734.","journal-title":"Biomed Pharmacother"},{"key":"3253_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.14230","volume":"46","author":"N Chandrashekar","year":"2022","unstructured":"Chandrashekar N, Pandi A. Baicalein: a review on its anti-cancer effects and mechanisms in lung carcinoma. J Food Biochem. 2022;46:e14230. https:\/\/doi.org\/10.1111\/jfbc.14230.","journal-title":"J Food Biochem"},{"key":"3253_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113991","volume":"157","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang H, Xiong J, Zhao J, Guo M, Chen J, et al. Icariin as an emerging candidate drug for anticancer treatment: current status and perspective. Biomed Pharmacother. 2023;157:113991. https:\/\/doi.org\/10.1016\/j.biopha.2022.113991.","journal-title":"Biomed Pharmacother"},{"key":"3253_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110013","volume":"125","author":"Y-S Sun","year":"2020","unstructured":"Sun Y-S, Thakur K, Hu F, Cespedes-Acu\u00f1a CL, Zhang J-G, Wei Z-J. Icariside II suppresses cervical cancer cell migration through JNK-modulated matrix metalloproteinase-2\/9 Inhibition in Vitro and in Vivo. Biomed Pharmacother. 2020;125:110013. https:\/\/doi.org\/10.1016\/j.biopha.2020.110013.","journal-title":"Biomed Pharmacother"},{"key":"3253_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104616","volume":"152","author":"Y-S Sun","year":"2020","unstructured":"Sun Y-S, Thakur K, Hu F, Zhang J-G, Wei Z-J. Icariside II inhibits tumorigenesis via inhibiting Akt\/Cyclin E\/ Cdk 2 pathway and activating mitochondria-dependent pathway. Pharmacol Res. 2020;152:104616. https:\/\/doi.org\/10.1016\/j.phrs.2019.104616.","journal-title":"Pharmacol Res"},{"key":"3253_CR27","first-page":"5819","volume":"7","author":"D Tao","year":"2014","unstructured":"Tao D, Pan Y, Lu H, Zheng S, Lin H, Fang H, et al. B-Myb is a gene implicated in cell cycle and proliferation of breast cancer. Int J Clin Exp Pathol. 2014;7:5819\u201327.","journal-title":"Int J Clin Exp Pathol"},{"key":"3253_CR28","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1099\/vir.0.035352-0","volume":"92","author":"N Nor Rashid","year":"2011","unstructured":"Nor Rashid N, Yusof R, Watson RJ. Disruption of repressive P130-dream complexes by human papillomavirus 16 E6\/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J Gen Virol. 2011;92:2620\u20137. https:\/\/doi.org\/10.1099\/vir.0.035352-0.","journal-title":"J Gen Virol"},{"key":"3253_CR29","first-page":"1542","volume":"5","author":"F Ren","year":"2015","unstructured":"Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei P, et al. Mybl2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res. 2015;5:1542\u201352.","journal-title":"Am J Cancer Res"},{"key":"3253_CR30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/hep.24174","volume":"53","author":"DF Calvisi","year":"2011","unstructured":"Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, Tomasi ML, et al. Activation of V-Myb avian myeloblastosis viral oncogene homolog-like2 (Mybl2)-Lin9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant P53. Hepatology. 2011;53:1226\u201336. https:\/\/doi.org\/10.1002\/hep.24174.","journal-title":"Hepatology"},{"key":"3253_CR31","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1158\/1078-0432.CCR-10-3244","volume":"17","author":"G Zauli","year":"2011","unstructured":"Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, et al. Mir-34a induces the downregulation of both E2f1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 2011;17:2712\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3244.","journal-title":"Clin Cancer Res"},{"key":"3253_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/onc.2016.181","volume":"36","author":"F Iltzsche","year":"2017","unstructured":"Iltzsche F, Simon K, Stopp S, Pattschull G, Francke S, Wolter P, et al. An important role for Myb-Muvb and its target gene Kif23 in a mouse model of lung adenocarcinoma. Oncogene. 2017;36:110\u201321. https:\/\/doi.org\/10.1038\/onc.2016.181.","journal-title":"Oncogene"},{"key":"3253_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.18632\/oncotarget.138","volume":"1","author":"F Gualdrini","year":"2010","unstructured":"Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschell\u00e0 G, et al. Addiction of Mycn amplified tumours to B-Myb underscores a reciprocal regulatory loop. Oncotarget. 2010;1:278\u201388.","journal-title":"Oncotarget"},{"key":"3253_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0412-y","volume":"32","author":"D Tao","year":"2015","unstructured":"Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin H, et al. B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell. Med Oncol. 2015;32:412. https:\/\/doi.org\/10.1007\/s12032-014-0412-y.","journal-title":"Med Oncol"},{"key":"3253_CR35","first-page":"6803","volume":"62","author":"A Bar-Shira","year":"2002","unstructured":"Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002;62:6803\u20137.","journal-title":"Cancer Res"},{"key":"3253_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/onc.2008.430","volume":"28","author":"AR Thorner","year":"2009","unstructured":"Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 2009;28:742\u201351. https:\/\/doi.org\/10.1038\/onc.2008.430.","journal-title":"Oncogene"},{"key":"3253_CR37","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2147\/OTT.S190145","volume":"12","author":"H Qin","year":"2019","unstructured":"Qin H, Li Y, Zhang H, Wang F, He H, Bai X, et al. Prognostic implications and oncogenic roles of Mybl2 protein expression in esophageal squamous-cell carcinoma. Onco Targets Ther. 2019;12:1917\u201327. https:\/\/doi.org\/10.2147\/OTT.S190145.","journal-title":"Onco Targets Ther"},{"key":"3253_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/excr.1999.4742","volume":"254","author":"A Engelhard","year":"2000","unstructured":"Engelhard A, Campbell K, Calabretta B. B-Myb alters the response of myeloid precursor cells to G-Csf. Exp Cell Res. 2000;254:153\u201362.","journal-title":"Exp Cell Res"},{"key":"3253_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.retram.2017.11.002","volume":"66","author":"Z Guan","year":"2018","unstructured":"Guan Z, Cheng W, Huang D, Wei A. High Mybl2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med. 2018;66:27\u201332. https:\/\/doi.org\/10.1016\/j.retram.2017.11.002.","journal-title":"Curr Res Transl Med"},{"key":"3253_CR40","doi-asserted-by":"publisher","unstructured":"Pattschull G, Walz S, Gr\u00fcndl M, Schwab M, R\u00fchl E, Baluapuri A, et al. The Myb-Muvb complex is required for Yap-dependent transcription of mitotic genes. Cell Rep 2019;27. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.071.","DOI":"10.1016\/j.celrep.2019.05.071"},{"key":"3253_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3727\/096504017X15135941182107","volume":"26","author":"J Chen","year":"2018","unstructured":"Chen J, Chen X. Mybl2 is targeted by Mir-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol Res. 2018;26:913\u201322. https:\/\/doi.org\/10.3727\/096504017X15135941182107.","journal-title":"Oncol Res"},{"key":"3253_CR42","doi-asserted-by":"publisher","unstructured":"Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y, et al. B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int J Mol Sci 2017;18. https:\/\/doi.org\/10.3390\/ijms18060860.","DOI":"10.3390\/ijms18060860"},{"key":"3253_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11010-020-03721-x","volume":"468","author":"Y-C Xiong","year":"2020","unstructured":"Xiong Y-C, Wang J, Cheng Y, Zhang X-Y, Ye X-Q. Overexpression of Mybl2 promotes proliferation and migration of non-small-cell lung cancer via upregulating Ncaph. Mol Cell Biochem. 2020;468:185\u201393. https:\/\/doi.org\/10.1007\/s11010-020-03721-x.","journal-title":"Mol Cell Biochem"},{"key":"3253_CR44","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.leukres.2013.09.015","volume":"37","author":"O Fuster","year":"2013","unstructured":"Fuster O, Llop M, Dolz S, Garc\u00eda P, Such E, Ib\u00e1\u00f1ez M, et al. Adverse prognostic value of Mybl2 overexpression and association with MicroRNA-30 family in acute myeloid leukemia patients. Leuk Res. 2013;37:1690\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2013.09.015.","journal-title":"Leuk Res"},{"key":"3253_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00825","volume":"2","author":"S Heinrichs","year":"2013","unstructured":"Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, et al. Mybl2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013;2:e00825. https:\/\/doi.org\/10.7554\/eLife.00825.","journal-title":"Elife"},{"key":"3253_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.prp.2017.04.024","volume":"213","author":"R Yu","year":"2017","unstructured":"Yu R, Li C, Lin X, Chen Q, Li J, Song L, et al. Clinicopathologic features and prognostic implications of Mybl2 protein expression in pancreatic ductal adenocarcinoma. Pathol Res Pr. 2017;213:964\u20138. https:\/\/doi.org\/10.1016\/j.prp.2017.04.024.","journal-title":"Pathol Res Pr"},{"key":"3253_CR47","first-page":"3365","volume":"59","author":"G Raschell\u00e0","year":"1999","unstructured":"Raschell\u00e0 G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, et al. Expression of B-Myb in neuroblastoma tumors is a poor prognostic factor independent from Mycn amplification. Cancer Res. 1999;59:3365\u20138.","journal-title":"Cancer Res"},{"key":"3253_CR48","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.1074\/jbc.270.15.8540","volume":"270","author":"G Raschell\u00e0","year":"1995","unstructured":"Raschell\u00e0 G, Negroni A, Sala A, Pucci S, Romeo A, Calabretta B. Requirement of B-Myb function for survival and differentiative potential of human neuroblastoma cells. J Biol Chem. 1995;270:8540\u20135.","journal-title":"J Biol Chem"},{"key":"3253_CR49","doi-asserted-by":"publisher","first-page":"706","DOI":"10.5858\/arpa.2018-0584-CP","volume":"144","author":"EE Walk","year":"2020","unstructured":"Walk EE, Yohe SL, Beckman A, Schade A, Zutter MM, Pfeifer J, et al. The cancer immunotherapy biomarker testing landscape. Arch Pathol Lab Med. 2020;144:706\u201324. https:\/\/doi.org\/10.5858\/arpa.2018-0584-CP.","journal-title":"Arch Pathol Lab Med"},{"key":"3253_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001.","journal-title":"Cancer Cell"},{"key":"3253_CR51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022;17:1335\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.109.","journal-title":"J Thorac Oncol"},{"key":"3253_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05674-7","volume":"14","author":"S Brahim","year":"2023","unstructured":"Brahim S, Negulescu A-M, Geneste C, Schott T, Lin S, Morel L-O, et al. Notch3 regulates Mybl2 via Heyl to limit proliferation and tumor initiation in breast cancer. Cell Death Dis. 2023;14:171. https:\/\/doi.org\/10.1038\/s41419-023-05674-7.","journal-title":"Cell Death Dis"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03253-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:54:19Z","timestamp":1768917259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03253-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Ethics Committee of Shanghai OUTDO BIOTECH Co., Ltd (Approval number: YBM-05-02), and informed consent was obtained from each patient in accordance with the Declaration of Helsinki. All animal experiments were approved by the Ethics Committee of Dalian Medical University on Laboratory Animal Care (Approval number: AEE21041).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}